IMUX vs. ALT

Last updated Apr 1, 2026

Compare and contrast key facts about Immunic, Inc. (IMUX) and Altimmune, Inc. (ALT).

Performance

IMUX vs. ALT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immunic, Inc. (IMUX) and Altimmune, Inc. (ALT). The values are adjusted to include any dividend payments, if applicable.

IMUX vs. ALT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
IMUX Immunic, Inc.	107.98%	-46.63%	-33.33%	7.14%	-85.37%	-37.41%	57.63%	30.17%	-96.87%	36.78%
ALT Altimmune, Inc.	-14.68%	-49.93%	-35.91%	-31.61%	79.59%	-18.79%	496.83%	-8.25%	-96.55%	-93.83%

Fundamentals

Market Cap IMUX : $1.73B ALT : $309.89M
EPS IMUX : -$0.15 ALT : -$0.97
Total Revenue (TTM) IMUX : $0.00 ALT : $41.00K
Gross Profit (TTM) IMUX : $0.00 ALT : -$14.95M
EBITDA (TTM) IMUX : -$103.23M ALT : -$89.46M

Returns By Period

In the year-to-date period, IMUX achieves a 107.98% return, which is significantly higher than ALT's -14.68% return. Over the past 10 years, IMUX has underperformed ALT with an annualized return of -44.16%, while ALT has yielded a comparatively higher -40.86% annualized return.

IMUX

• 1D: 7.77%
• 1M: 8.82%
• YTD: 107.98%
• 6M: 25.91%
• 1Y: 1.83%
• 3Y*: -9.35%
• 5Y*: -41.96%
• 10Y*: -44.16%

ALT

• 1D: 6.94%
• 1M: -28.54%
• YTD: -14.68%
• 6M: -18.30%
• 1Y: -38.40%
• 3Y*: -9.96%
• 5Y*: -26.13%
• 10Y*: -40.86%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

IMUX vs. ALT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMUX

IMUX Risk / Return Rank: 42
IMUX Sharpe Ratio Rank: 41
IMUX Sortino Ratio Rank: 47
IMUX Omega Ratio Rank: 45
IMUX Calmar Ratio Rank: 37
IMUX Martin Ratio Rank: 38

ALT

ALT Risk / Return Rank: 26
ALT Sharpe Ratio Rank: 23
ALT Sortino Ratio Rank: 31
ALT Omega Ratio Rank: 32
ALT Calmar Ratio Rank: 18
ALT Martin Ratio Rank: 24

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMUX vs. ALT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immunic, Inc. (IMUX) and Altimmune, Inc. (ALT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMUX	ALT	Difference
Sharpe ratio Return per unit of total volatility	0.02	-0.41	+0.43
Sortino ratio Return per unit of downside risk	0.68	0.05	+0.63
Omega ratio Gain probability vs. loss probability	1.08	1.01	+0.07
Calmar ratio Return relative to maximum drawdown	-0.12	-0.67	+0.55
Martin ratio Return relative to average drawdown	-0.21	-1.02	+0.81
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IMUX vs. ALT - Sharpe Ratio Comparison

The current IMUX Sharpe Ratio is 0.02, which is higher than the ALT Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of IMUX and ALT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	IMUX	ALT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.02	-0.41	+0.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.43	-0.28	-0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.38	-0.29	-0.09
Sharpe Ratio (All Time) Calculated using the full available price history	-0.35	-0.24	-0.10

Correlation

The correlation between IMUX and ALT is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

IMUX vs. ALT - Dividend Comparison

Neither IMUX nor ALT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

IMUX vs. ALT - Drawdown Comparison

The maximum IMUX drawdown since its inception was -99.96%, roughly equal to the maximum ALT drawdown of -99.94%. Use the drawdown chart below to compare losses from any high point for IMUX and ALT.

Drawdown Indicators

	IMUX	ALT	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	-99.94%	-0.02%
Max Drawdown (1Y) Largest decline over 1 year	-60.14%	-62.65%	+2.51%
Max Drawdown (5Y) Largest decline over 5 years	-96.97%	-90.45%	-6.52%
Max Drawdown (10Y) Largest decline over 10 years	-99.86%	-99.85%	-0.01%
Current Drawdown Current decline from peak	-99.92%	-99.89%	-0.03%
Average Drawdown Average peak-to-trough decline	-87.19%	-80.66%	-6.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.61%	41.12%	-5.51%

Volatility

IMUX vs. ALT - Volatility Comparison

Immunic, Inc. (IMUX) has a higher volatility of 34.50% compared to Altimmune, Inc. (ALT) at 26.59%. This indicates that IMUX's price experiences larger fluctuations and is considered to be riskier than ALT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IMUX	ALT	Difference
Volatility (1M) Calculated over the trailing 1-month period	34.50%	26.59%	+7.91%
Volatility (6M) Calculated over the trailing 6-month period	61.52%	58.39%	+3.13%
Volatility (1Y) Calculated over the trailing 1-year period	87.96%	93.96%	-6.00%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.70%	94.38%	+3.32%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	117.14%	142.47%	-25.33%

Financials